Sequencing costs come down, while patients’ wait continues
This article was originally published in Scrip
Executive Summary
Last Monday, the publication of a letter in Nature Biotechnology described the first “single-molecule sequencing of an individual human genome”, using a third-generation sequencing instrument by Helicos. While the sequencing of a whole human genome per se is no longer extraordinary, it is generally agreed that to make a patient’s DNA data available for a personalised medicine approach, the effort, time and money invested in sequencing a single person’s genome need to come down considerably.
You may also be interested in...
Biomarkers in Parkinson's disease – an open field with few obvious targets
The market for biomarkers in neurological diseases is an increasingly attractive one for many diagnostics companies. An improved understanding of the disorders and the possibility of disease-modifying drugs could lead to the discovery of more diagnostic markers and, hopefully, earlier diagnosis. In neurodegenerative illnesses, earlier intervention could stave off further loss of neurological function. This in turn would improve a patient's quality of life, and reduce the economic burden on society.
Qiagen scales its way up the IVD ladder through strategic acquisitions
Diagnostics clearly is the market to invest in. The last few years have seen companies with a mainly research-oriented customer base buying in more clinically-relevant companies. Invitrogen, for example, acquired Applied Biosystems last year and now, as Life Technologies, has a prime position in the next-generation sequencing market, while Thermo Electron added a huge healthcare customer base with the Fisher acquisition of 2006 and, last month, bought biomarker expert BRAHMS. Of course, there are the players from the medtech field, such as Siemens Healthcare, which made three big diagnostics investments in DPC, Bayer’s diagnostics business and Dade-Behring. Even an established diagnostics company like Beckman Coulter continues to buy in new assets and expand its geographical reach, such as with the Olympus diagnostics unit.
Qiagen aspires to leadership in personalised medicine
For anyone following the fastest-growing companies in the companion diagnostics sector, last month’s acquisition of DxS by Qiagen for up to $130m was no surprise. Qiagen has had its eye on personalised healthcare for quite a while now, and DxS is a very promising addition to the Venlo-based company.